BURLINGTON, Mass., July 24, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) will announce fiscal third quarter 2024 earnings which ended on June 30, 2024, on Tuesday, August 6, 2024, after the market closes.The Company will host a conference call and live webcast to discuss its financial results on the same day, Tuesday, August 6, 2024, at 4:30 p.m. Eastern Time. Analysts, investors and members of the media can access the live webcast via the Azenta website at https://investors.azenta.com/events. A replay ...

Core Insights - Azenta, Inc. is participating in the FinnGen project, a significant research initiative in personalized medicine in Finland, which involves genomic and health data from 500,000 Finnish biobank participants [1][3] - The company will provide proteomics profiling for up to 20,000 individuals using Olink's advanced technology, highlighting its commitment to healthcare innovation [1][2] - The collaboration aims to enhance understanding of disease mechanisms, identify new biomarkers, and develop targeted treatments [2][3] Company Overview - Azenta, Inc. is a leading provider of life sciences solutions, offering a range of services including cold-chain sample management and multiomics services for drug development and clinical research [4] - The company operates globally with a presence in North America, Europe, and Asia, supporting pharmaceutical, biotech, academic, and healthcare institutions [4] Project Significance - The FinnGen project is notable for its public-private partnership approach, aiming to create a world-class resource for future studies in personalized medicine [3] - The integration of proteomics with genomic data is expected to provide novel insights into health and disease, facilitating breakthroughs in prevention, diagnosis, and treatment [2][3]

Core Insights - Azenta, Inc. has been selected by the Crohn's & Colitis Foundation as the sample management services provider for two significant research cohorts, CAPTURE IBD and IBD SIRQC, focusing on pediatric and surgical care for inflammatory bowel disease [1][2] - The CAPTURE IBD study aims to enroll several thousand pediatric patients across 12 sites in the U.S., while the IBD SIRQC initiative plans to enroll 5,000 patients at 9 sites, tracking long-term surgical outcomes [2][3] - The partnership is expected to enhance the understanding of inflammatory bowel disease and support the development of precision medicine strategies [3] Company Overview - Azenta, Inc. is a leading provider of life sciences solutions, offering a comprehensive suite of cold-chain sample management and multiomics services to pharmaceutical, biotech, academic, and healthcare institutions globally [5] - The company is headquartered in Burlington, Massachusetts, with operations in North America, Europe, and Asia, and is known for its brands including GENEWIZ, FluidX, and others [5] Foundation Overview - The Crohn's & Colitis Foundation is a prominent nonprofit organization dedicated to research and patient support for inflammatory bowel disease, aiming to cure Crohn's disease and ulcerative colitis while improving the quality of life for affected individuals [4] - The Foundation's IBD Plexus® program provides a rich research ecosystem that links well-phenotyped data to biosamples, facilitating high-impact research [2][4]

BURLINGTON, Mass., May 23, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that Company management will participate in the Jefferies Global Healthcare Conference in New York, NY, on Wednesday, June 5, 2024, which includes a presentation beginning at 11:00 am ET. The live webcast can be accessed through the Azenta investor relations website at https://investors.azenta.com/events. A replay of the webcast will be available following the event.About Azenta Life SciencesAzenta, Inc. (Nasdaq: AZT ...

Core Viewpoint - The article discusses the impact of inflation on consumers and businesses, leading to a rise in automation and robotics adoption, while highlighting specific robotics stocks that are recommended to sell due to declining performance and macroeconomic challenges [1]. Group 1: iRobot (IRBT) - iRobot has seen a significant contraction in sales growth, with revenue declining by more than 24% year-over-year for both fiscal years 2022 and 2023, marking the first time since 2017 that annual revenue fell below $1 billion [2][3]. - The decline in consumer confidence and high costs of new technologies have deterred purchases, prompting iRobot to announce a restructuring plan in January 2024, which includes operational cost cuts and leadership changes [3]. Group 2: Rockwell Automation (ROK) - Rockwell Automation operates in various industrial sectors but has faced sales declines, particularly in discrete and automotive sales, which fell in the "high single digits" due to challenges in the electric vehicle market [4][5]. - The company also reported declines in e-commerce and warehousing sales due to delayed modernization projects, with shares down 11.1% year-to-date as of the last trading session [5]. Group 3: Azenta (AZTA) - Azenta, a life sciences firm, has experienced a 13% year-over-year revenue decline in Q1 2024, with only a 7% increase in the second quarter, indicating weak sales growth for a largely loss-making company [6][7]. - Investors are concerned about Azenta's ability to reach breakeven, as the current revenue growth is insufficient to support its financial stability [7].

"We're thrilled to open our Oxford laboratory, which allows us to bring state-of-the-art NGS technology to UK researchers," said Dr Ginger Zhou, President of Azenta's Multiomics business unit.  "This new facility not only strengthens our global footprint but also offers researchers access to local experts and cutting-edge resources. The Oxford team comprises some of the best minds in the field, all with deep roots in the local scientific community." The opening event, held on April 25, 2024, featured a ribb ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: March 31, 2024 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from __________ to _________ Commission File Number 000-25434 AZENTA, INC. (Exact name of registrant as specified in its charter) Delaware 04-30 ...

Azenta, Inc. (NASDAQ:AZTA) Q2 2024 Results Conference Call May 8, 2024 4:30 PM ET Company Participants Yvonne Perron - Vice President, FP&A and Investor Relations Steve Schwartz - President and Chief Executive Officer Herman Cueto - Chief Financial Officer Conference Call Participants David Saxon - Needham Hannah Hefley - Stephens Vijay Kumar - Evercore ISI Yuan Zhi - B. Riley Matt Stanton - Jefferies Operator Greetings, and welcome to the Azenta Second Quarter 2024 Financial Results. [Operator Instructions ...

Exhibit 99.1 Azenta Reports Second Quarter Results for Fiscal 2024, Ended March 31, 2024 BURLINGTON, Mass., May 8, 2024 (PR Newswire) – Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the second quarter ended March 31, 2024. | --- | --- | --- | --- | --- | --- | --- | --- | --- | |--------------------------------------------------------|-------|----------------------|-------|-------------------------|---------|------------------------------|----------------------|-------------| | Dollars in ...

CEO Dr. Stephen Schwartz to Retire; Search Underway to Identify Successor BURLINGTON, Mass., May 8, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced a CEO succession plan, under which CEO and Board Director Dr. Stephen Schwartz will be retiring from Azenta after more than 14 years of service. Dr. Schwartz will continue to serve as CEO until a successor is appointed to ensure a smooth transition. Dr. Schwartz's retirement follows a discussion with the Board as part of the company's active suc ...